



# ReVivo Medical

## Press Release

### **ReVivo Medical Reaches Milestone of 50<sup>th</sup> Surgical Procedure of its Anterior Cervical Discectomy & Fusion Devices**

October 7, 2025. ReVivo Medical announced today that it has successfully completed the 50<sup>th</sup> surgical procedure using the Company's innovative anterior cervical plates and interbody cages. "We were required to perform 50 surgical procedures as part of our FDA sanctioned IDE clinical trial, a requirement for attaining regulatory clearance prior to offering a commercial product," explains Gary Mittleman, president and CEO. "Although final clearance requires us to track patients for 2-years post-surgery we are very pleased with our device's performance thus far."

"Anterior cervical plates and interbody cages are used in over 400,000 surgical procedures each year representing a multi-billion-dollar market," says Dr. Darryl DiRisio, Chief Medical Officer. "The primary measure of success in these operations is the rapid achievement of bone fusion which thereby stabilizes the spine and eliminates pain."

The trial surgical procedures took place at Albany Medical Center, the Cleveland Clinic, University at Buffalo Neurosurgery, and IGEA Brain and Spine. Study participants received ReVivo Medical's next generation CEM-Plate™ and CEM-Cage™ used in anterior cervical discectomy and fusion procedures.

"Through the clinical trial, we hope to demonstrate that our cervical plate and cage implants improve patient outcomes and provide advantages for the surgeon," explains Eric Ledet, Ph.D., Chief Operating Officer. "We plan to report our complete findings to the FDA in late 2027."

**About ReVivo Medical, Inc.**, head-quartered in Albany, New York, is developing implantable medical devices for use by surgeons on patients with spinal pathology. The founders, Darryl DiRisio, MD, Professor, Chair of Neurosurgery and A. John Popp Chair of Spinal Surgery at Albany Medical Center and biomedical engineers Eric Ledet, PhD. and Glenn Sanders, PhD. teamed up with the aim of developing products that improve patient health, facilitate easier surgery and reduce costs in this ever-competitive healthcare arena.

*None of ReVivo Medical's devices are currently cleared for sale or use in the United States.*



# ReVivo Medical

**To learn more please visit our website:**

ReVivo Medical, Inc. [www.revivomedical.com](http://www.revivomedical.com)

**Contacts:**

Gary Mittleman, President and CEO (518) 527-4747 or [gmittleman@revivomedical.com](mailto:gmittleman@revivomedical.com)

Eric Ledet, PhD., Chief Operating Officer (518) 227-0743 [eledet@revivomedical.com](mailto:eledet@revivomedical.com)

**Cautionary Statement Regarding Forward Looking Statements**

This press release contains forward-looking statements that are not purely historical regarding ReVivo Medical's or its management's intentions, beliefs, expectations and strategies for the future, including those relating to the development, cost, size, intended use and technical specifications of the medical products, the potential impact on outcomes and costs associated with spinal surgeries, and the potential profits to be made by ReVivo Medical pursuant to the successful commercialization of their product(s) and the size of market and market share of products. Because such statements deal with future events, they are subject to various risks and uncertainties, and actual results could differ materially from ReVivo Medical's current expectations. Factors that could cause actual results to differ materially include risks and uncertainties such as those relating to: the inability to successfully develop new products and obtain regulatory approval; insufficient outcomes in a clinical trial to achieve clearance; a lack of acceptance in the marketplace by physicians and patients; the inability to manufacture products in commercial quantities at an acceptable cost; possible delays in the company's development programs; the inability of patients or hospitals to receive reimbursement from third-party payors; inadequate protection from patents to prohibit competitors from making similar devices; and inadequate financial and other resources.

All forward-looking statements and reasons why results might differ included in this release are made as of the date of this press release, based on information currently available to ReVivo Medical, and ReVivo Medical assumes no obligation to update any such forward-looking statement or reasons why results might differ.